Skip to main content
. 2018 Dec 29;8(1):30. doi: 10.3390/jcm8010030

Figure 1.

Figure 1

Flow diagram of the patient selection, allocation and analysis. HCC, hepatocellular carcinoma; non-HCC, non-hepatocellular carcinoma; EAD, early allograft dysfunction; NMR, nuclear 1H-nuclear magnetic resonance spectroscopy; LC-MS, liquid chromatography coupled with mass spectrometry.